The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes

Cell Communication & Adhesion
Martin StahlhutM Teresa Ramirez

Abstract

Rotigaptide (formerly ZP123) is a novel antiarrhythmic peptide that prevents uncoupling of connexin 43 (Cx43)-mediated, gap junction communication during acute metabolic stress. Since rotigaptide's long-term effects on Cx43 are unknown, we studied its effect on Cx43 protein levels at 24 h in neonatal ventricular myocytes. As determined by Western blot analysis, rotigaptide produced a dose-dependent increase in Cx43 protein expression that reached a maximum level at 100 nM. Furthermore, 100 nM rotigaptide markedly increased Cx43 immunoreactivity and Cx43-positive gap junctions as observed in immunocytochemical studies. Cycloheximide, an inhibitor of protein synthesis, was used to investigate rotigaptide's mechanism of action. Cycloheximide (10 microg/ml) reduced Cx43 protein levels to 39% of vehicle (17 mM ethanol) whereas cotreatment of 10 microg/ml cycloheximide with 100 nM rotigaptide reduced Cx43 protein levels to 56% of vehicle. Our findings suggest that rotigaptide's effect on Cx43 expression is partly due to increased biosynthesis.

References

Dec 1, 1985·The Biochemical Journal·C S Chandler, F J Ballard
Jan 22, 2000·The Journal of Clinical Investigation·Z AiG I Fishman
Aug 15, 2000·The Journal of Biological Chemistry·L S MusilL M Roberts
Jul 27, 2001·Cardiovascular Research·A A van VeenT Opthof
Jun 1, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stephan WengStefan Dhein
Jun 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Anne Louise KjølbyeJorgen Søberg Petersen
Apr 20, 2004·Cardiovascular Research·Viviana M BerthoudEric C Beyer
Sep 15, 2004·Alcoholism, Clinical and Experimental Research·Kirsten WentlandtPeter L Carlen
May 10, 2005·Journal of Cardiovascular Electrophysiology·Ketil HauganMorten Schak Nielsen

❮ Previous
Next ❯

Citations

Mar 4, 2014·FEBS Letters·Nikki L Farnsworth, Richard K P Benninger
Jan 18, 2014·FEBS Letters·Dale W Laird
May 11, 2011·The Journal of Cell Biology·Katharina da Silva LopesMichael Gotthardt
Jun 13, 2009·Journal of Electrocardiology·Bramah Singh
Oct 27, 2015·European Journal of Pharmacology·Pecoraro MichelaPopolo Ada
Sep 12, 2007·Basic & Clinical Pharmacology & Toxicology·Anne Louise KjølbyeJørgen S Petersen
Apr 1, 2008·Journal of Cardiovascular Electrophysiology·Marc Cohen, Gerald V Naccarelli
Jul 27, 2006·Basic & Clinical Pharmacology & Toxicology·Ketil HauganMasamichi Hirose
Jan 27, 2011·British Journal of Pharmacology·Elke De VuystLuc Leybaert
Jun 15, 2007·The Journal of Membrane Biology·Lene Nygaard AxelsenMorten Schak Nielsen
Mar 28, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Jennifer A EastonPatricia E M Martin
Nov 28, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Stefan DheinFriedrich-Wilhelm Mohr
Oct 11, 2008·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yan LiuLiang Liu
Dec 18, 2012·Calcified Tissue International·Elina KylmäojaJuha Tuukkanen
Apr 28, 2018·International Journal of Molecular Sciences·Trond AasenMichael Koval
Dec 1, 2017·Cell and Tissue Research·Ajaz Ahmad WazaBashir A Ganai
Jun 21, 2020·International Journal of Molecular Sciences·Seyed Mojtaba GhiasiThomas Mandrup-Poulsen
May 29, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Justine PatinMickaël Derangeon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.